PRODUCT

Adipotide (10 mg Vial)

No short description available.

Quickstart Highlights

Adipotide is a synthetic peptidomimetic that targets prohibitin on blood vessels within white adipose tissue and delivers a pro‑apoptotic sequence to destroy those vessels[1][2], resulting in targeted fat mass reduction as fat cells lose their blood supply[8]. Preclinical studies showed notable weight loss in obese rodents and primates[1][9]; however, clinical development was discontinued after a Phase 1 trial due to safety concerns[3][4]. This educational protocol presents a cautious once‑daily subcutaneous titration approach with careful dose escalation.

Reconstitute: Add 3.0 mL bacteriostatic water (max vial capacity) → ~3.33 mg/mL concentration.
Starting dose: 250 mcg once daily; gradual escalation by 250 mcg every 2 weeks as tolerated.
Easy measuring: At 3.33 mg/mL, 1 unit = 0.01 mL ≈ 33.33 mcg on a U‑100 insulin syringe.
Storage: Lyophilized: freeze at −20 °C (−4 °F); after reconstitution, refrigerate at 2–8 °C (35.6–46.4 °F); avoid freeze–thaw cycles[5].

Reconstitution

Draw 3.0 mL bacteriostatic water with a sterile syringe.
Inject slowly down the vial wall; avoid foaming.
Gently swirl/roll until dissolved (do not shake).
Label and refrigerate at 2–8 °C (35.6–46.4 °F) , protected from light [5] .
Label and refrigerate at 2–8 °C (35.6–46.4 °F), protected from light[5].

Protocol Overview

Goal:Targeted reduction of fat mass via vascular targeting in adipose tissue[2][8].
Schedule:Daily subcutaneous injections for 4–8 weeks (cautious approach due to limited human data)[3][9].
Dose Range:250–1000 mcg daily with gradual titration every 2 weeks.
Reconstitution:3.0 mL per 10 mg vial (~3.33 mg/mL) for accurate unit measurements.
Storage:Lyophilized frozen; reconstituted refrigerated; avoid repeated freeze–thaw[5].

Dosage Protocols

Start:250 mcg daily for Weeks 1–2; increase by 250 mcg every 2 weeks as tolerated[3][9].
Target:Up to 1000 mcg (1.0 mg) daily by Weeks 7–8 (if well‑tolerated).
Frequency:Once per day (subcutaneous).
Cycle Length:4–8 weeks (based on preclinical effective treatment duration; extend with extreme caution).
Timing:Any consistent time; rotate injection sites systematically.

Storage Instructions

Lyophilized:Store at −20 °C (−4 °F) in dry, dark conditions; minimize moisture exposure[5].
Reconstituted:Refrigerate at 2–8 °C (35.6–46.4 °F); prepare aliquots if needed and avoid freeze–thaw[5].

Important Notes

Practical considerations for consistency and safety.

Use new sterile insulin syringes; dispose in a sharps container.
Rotate injection sites (abdomen, thighs, upper arms) to reduce local irritation.
Inject slowly; wait a few seconds before withdrawing the needle[6][7].
Document daily dose and site rotation to maintain consistency.
Safety consideration: Clinical development was discontinued due to safety concerns including reversible kidney toxicity at higher doses[3][4]. This protocol is for educational purposes only.

How It Works

Adipotide is a peptidomimetic compound designed to selectively target blood vessels within white adipose tissue by binding to prohibitin‑1 on the vascular endothelium[2][8]. Once bound, it delivers a pro‑apoptotic sequence that triggers vessel destruction, cutting off the blood supply to fat cells and causing them to undergo apoptosis and be metabolized[1][2]. Preclinical studies in obese rodents demonstrated approximately 30% body weight reduction, and obese primates showed about 11% weight loss after 4 weeks of treatment[1][9]. A first‑in‑human Phase 1 trial was initiated in obese cancer patients[3], but further clinical development was discontinued due to strategic and safety reasons, including reversible renal effects observed at higher doses[4].

Lifestyle Factors

Pair with a balanced, protein‑forward diet tailored to energy needs.
Combine resistance training and aerobic activity to reinforce metabolic adaptations.
Prioritize sleep and stress management to support adherence and recovery.
Monitor kidney function if extending beyond initial 4‑week cycle due to preclinical observations of renal effects.

Injection Technique

Clean the vial stopper and skin with alcohol; allow to dry fully.
Pinch a skinfold; insert the needle at 45–90° into subcutaneous tissue (45° if limited subcutaneous fat, 90° if ample tissue)[6].
Do not aspirate for subcutaneous injections; inject slowly and steadily[7].
Rotate sites systematically (abdomen, thighs, upper arms) to avoid lipohypertrophy and local irritation.
Wait a moment before withdrawing the needle; apply gentle pressure but do not rub the injection site.

Benefits and Side Effects

Benefits

Preclinical studies showed notable targeted fat mass reduction (up to 30% body weight in rodents, ~11% in primates over 4 weeks)[1][2][8][9].
Mechanism specifically targets adipose tissue vasculature, sparing other tissues in preclinical models[2].
Safety concerns: Clinical development was discontinued due to safety issues[3][4]; reversible kidney toxicity was dose‑dependent in preclinical studies[1].
Limited human data: Only Phase 1 trial data available; long‑term safety profile in humans is unknown.

Side Effects

Mild injection‑site reactions (redness, swelling) may occur with subcutaneous administration.

Adipotide (10 mg Vial)

Resources

Categories

Company